Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGN-195263
- Development stage
- Phase 2
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Topical, Ophthalmic
01
Overview
AGN-195263 is a small molecule drug developed as a topical ophthalmic treatment for eye disorders, primarily targeting meibomian gland dysfunction and evaporative dry eye. The drug was originally developed by Allergan and later by AbbVie following Allergan's acquisition. It reached phase III clinical trials for dry eyes and phase II for meibomianitis but development appears to have been discontinued. The precise mechanism of action remains undefined, but it was investigated as a new molecular entity for improving symptoms associated with tear film instability and eyelid gland dysfunction[1][2][3][4].
- Other names
- AGN 195263AGN195263AGN-195263
02
Targets
RARG (Retinoic acid receptor gamma)
Beyond the preview
Go deeper on AGN-195263.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGN-195263.